Neumora Therapeutics Statistics
Total Valuation
NMRA has a market cap or net worth of $104.06 million. The enterprise value is $40.47 million.
| Market Cap | 104.06M |
| Enterprise Value | 40.47M |
Important Dates
The next estimated earnings date is Tuesday, November 17, 2026, before market open.
| Earnings Date | Nov 17, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
NMRA has 187.90 million shares outstanding. The number of shares has increased by 8.03% in one year.
| Current Share Class | 187.90M |
| Shares Outstanding | 187.90M |
| Shares Change (YoY) | +8.03% |
| Shares Change (QoQ) | +2.94% |
| Owned by Insiders (%) | 4.42% |
| Owned by Institutions (%) | 41.03% |
| Float | 116.41M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 2.08 |
| P/TBV Ratio | 2.09 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.50, with a Debt / Equity ratio of 1.20.
| Current Ratio | 4.50 |
| Quick Ratio | 4.21 |
| Debt / Equity | 1.20 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -31.94 |
Financial Efficiency
Return on equity (ROE) is -187.11% and return on invested capital (ROIC) is -85.76%.
| Return on Equity (ROE) | -187.11% |
| Return on Assets (ROA) | -73.85% |
| Return on Invested Capital (ROIC) | -85.76% |
| Return on Capital Employed (ROCE) | -211.58% |
| Weighted Average Cost of Capital (WACC) | 17.18% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$3.38M |
| Employee Count | 63 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, NMRA has paid $30,000 in taxes.
| Income Tax | 30,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -81.66% in the last 52 weeks. The beta is 3.14, so NMRA's price volatility has been higher than the market average.
| Beta (5Y) | 3.14 |
| 52-Week Price Change | -81.66% |
| 50-Day Moving Average | 0.75 |
| 200-Day Moving Average | 1.76 |
| Relative Strength Index (RSI) | 52.54 |
| Average Volume (20 Days) | 1,945,730 |
Short Selling Information
The latest short interest is 5.64 million, so 3.00% of the outstanding shares have been sold short.
| Short Interest | 5.64M |
| Short Previous Month | 6.69M |
| Short % of Shares Out | 3.00% |
| Short % of Float | 4.84% |
| Short Ratio (days to cover) | 2.30 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -206.23M |
| Pretax Income | -212.72M |
| Net Income | -212.75M |
| EBITDA | -206.19M |
| EBIT | -206.23M |
| Earnings Per Share (EPS) | -$1.22 |
Balance Sheet
The company has $116.83 million in cash and $53.25 million in debt, with a net cash position of $63.58 million or $0.34 per share.
| Cash & Cash Equivalents | 116.83M |
| Total Debt | 53.25M |
| Net Cash | 63.58M |
| Net Cash Per Share | $0.34 |
| Equity (Book Value) | 44.52M |
| Book Value Per Share | 0.24 |
| Working Capital | 97.10M |
Cash Flow
| Operating Cash Flow | -180.52M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 47,000 |
| Net Borrowing | 38.76M |
| Free Cash Flow | -180.52M |
| FCF Per Share | -$0.96 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
NMRA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -8.03% |
| Shareholder Yield | -8.03% |
| Earnings Yield | -220.96% |
| FCF Yield | -193.82% |
Analyst Forecast
The average price target for NMRA is $6.00, which is 983.42% higher than the current price. The consensus rating is "Buy".
| Price Target | $6.00 |
| Price Target Difference | 983.42% |
| Analyst Consensus | Buy |
| Analyst Count | 9 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |